FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2354474489> ?p ?o ?g. }

• W2354474489 abstract "Neuropathic pain is a debilitating condition that affects millions of Americans. Despite decades of research, the disease is refractory to current treatments in a substantial population of patients. Recent advances in the understanding of neuropathic pain have led to the targeting of glial cells to better control the condition. Current clinical therapies do not manage the inflammatory response that originates with glial cells and contributes to this affliction. IL-10 is an anti-inflammatory cytokine that attenuates the inflammatory response that occurs at the neuroimmune interface in neuropathic pain models. IL-10 gene therapy has alleviated neuropathic pain in a number of animal studies. We tested whether gene therapy increasing the expression of IL-10 and IL-10R1 could attenuate allodynia in a chronic constriction injury (CCI) model of neuropathic pain. Our experiments did not produce reversal of neuropathic pain using the combined gene therapy. However, the CCI surgeries did not produce neuropathic pain in the male mice. While the female mice developed neuropathic pain, the expression of plasmid genes could not be definitively confirmed. Therefore, while the present study did not provide convincing evidence that the combined gene therapy could alleviate neuropathic pain, additional experiments should be performed to further investigate the potential of combined IL-10/IL-10R1 gene therapy for combating neuropathic pain and to investigate the sex differences in the biochemical pathways underlying neuropathic pain. Introduction Neuropathic pain is a debilitating illness that affects a large portion of the world population. It arises as a direct consequence of a lesion or disease affecting the somatosensory system (Treede et al., 2008). Studies have reported variable numbers for the prevalence of neuropathic pain, ranging from 1.5% to 8% (Taylor, 2006; Torrance et al., 2006; Bouhassira et al., 2008). Regardless of where the prevalence falls within this range, millions of Americans and millions more worldwide are affected. Neuropathic pain is expensive to manage and significantly decreases the quality of life of afflicted patients (Taylor, 2006). Intrathecal delivery of IL-10 gene therapy has shown promise in alleviating neuropathic pain in an animal model of neuropathic pain in several studies (Milligan et al., 2005a, 2005b, 2006a, 2006b; Ledeboer et al., 2007; Sloane et al., 2009a, 2009b; Soderquist et al., 2010). We hypothesized that overexpressing IL-10R1, part of the IL-10 receptor, could enhance the effectiveness of IL-10 gene therapy. To test this hypothesis, we acquired an AAV9 viral vector that leads to overexpression of the IL-10 receptor (IL-10R1). This technique extends the effective duration of the pain relief (Figure 1). In addition, a recent report suggests that chronic pain develops by different cellular mechanisms in males and females (Sorge et al., 2015). This is of particular concern because the studies of IL-10 gene therapy have been conducted almost exclusively in male animals (Kwilasz et al., 2014), but the majority of chronic pain patients are female (Torrance et al., 2006). My work compared the efficacy of combined IL-10 and IL-10R1 gene therapy in both male and female mice to determine whether over-expression of the IL-10 receptor could create a longer-lasting reversal of allodynia than treatment with IL-10 gene therapy alone. Aims 1. Compare the effects of combined IL-10 and IL-10R1 gene therapy, as compared to each gene therapy technique in isolation, to determine if the combined therapy creates a longer duration anti-allodynia. 2. Compare the anti-allodynic effects of IL-10 gene therapy techniques in male and female mice. 3. Quantify expression of IL-10, IL-10R1, P2X4, and neuroinflammatory markers at different time points after surgery to determine the effects of gene therapy treatments on mRNA expression. Background Neuropathic Pain Neuropathic pain is a debilitating condition that affects a large portion of the world population. It arises as a direct consequence of a lesion or disease affecting the somatosensory system (Treede et al., 2008). A conservative estimate by Taylor (Taylor, 2006) predicts that the prevalence of neuropathic pain is 1.5%; studies in France and Britain have arrived at higher estimates of 7-8% of the population (Torrance et al., 2006; Bouhassira et al., 2008). Regardless of the exact number, millions of Americans suffer from neuropathic pain, presenting a significant clinical challenge. Despite years of research, current therapeutics do not effectively manage neuropathic pain in a substantial population of patients. Notably, all currently approved therapeutics focus on regulating neuronal processes. However, recent evidence has implicated glial cells, specifically microglia and astrocytes, as the major players in the induction and maintenance of neuropathic pain (Watkins et al., 2001; Watkins and Maier, 2003). Specifically, inflammation has been implicated as a key mechanism underlying the condition, and glial cells play an important role in generating the inflammatory response (Grace et al., 2014). Taken together, these findings make the inhibiting the inflammatory response produced by glial cells a key target for drug discovery. Neuroimmune Signaling The neuroimmune signaling generated by activated glial cells plays a key role in initiating and maintaining neuropathic pain (Grace et al., 2014). Three key cytokines among the myriad of pro-inflammatory substances that are released are tumor necrosis factor (TNF), interleukin-1 (IL-1), and interleukin 6 (IL-6). The neuroimmune interface is extremely complex, with a number of parallel and redundant mechanisms that can enhance pain signals. Two general mechanisms contribute to the neuroimmune enhancement of pain: the enhancement of excitatory synaptic transmissions, and the attenuation of inhibitory synaptic messages (Grace et al., 2014). Within each of these broad categories, multiple distinct pathways exist that can each enhance pain signaling and contribute to neuropathic pain (Grace et al., 2014). Pharmacological substances exist which can inhibit the actions of IL-1 and TNF (Watkins and Maier, 2003, 2004). However, blocking the actions of single pro-inflammatory cytokines is not a viable clinical approach. One issue is that these cytokines perform redundant functions. For example, if IL-1 is pharmacologically inhibited, TNF can perform the same biochemical actions as IL-1 (Watkins and Maier, 2003; Grace et al., 2014). Additionally, the potential effectiveness of inhibiting these molecules is limited by the fact that they perform important protective functions in the neuroimmune interface (Grace et al., 2014). Specifically, both TNF and IL-1 promote neuronal regeneration in different parts of the nervous system (Fontaine et al., 2002; Nadeau et al., 2011). Taken in combination, the presence of redundant mechanisms and the beneficial effects of proinflammatory cytokines in certain situations disqualifies the inhibition of any specific substance as a viable therapeutic method for neuropathic pain. Instead of inhibiting one or more proinflammatory cytokines, introducing a cytokine with broad-spectrum anti-inflammatory properties presents an alternate approach (Watkins and Maier, 2003; Grace et al., 2014). IL-10 A promising candidate for attenuating neuropathic pain is the anti-inflammatory cytokine IL-10 (Watkins and Maier, 2003, 2004). IL-10 performs potent anti-inflammatory actions. Neurons, astrocytes, and microglial cells in the CNS express IL-10. Activation of the IL-10 receptor has been shown to inhibit the release of numerous pro-inflammatory cytokines, including TNF, IL-1β, and IL-6 (Kwilasz et al., 2014). Additionally, IL-10 receptor activation stimulates the release of factors which mediate pro-inflammatory cytokines, including IL-1 receptor antagonist (Kwilasz et al., 2014). IL-10 exhibits neuroprotective properties through multiple mechanisms. Its inhibition of microglial secretion of pro-inflammatory cytokines increases excitatory amino acid transporter-2 (EAAT2) expression. This, in turn, reduces the buildup of excitatory amino acids and consequently prevents the neurotoxic effects of glutamate buildup (Bachis et al., 2001; Kim et al., 2011). IL-10 also appears to directly promote neuronal survival. Specific subsets of neurons display IL-10 receptors, and the activation of these receptors can promote neuron survival (Boyd et al., 2003). Taken together, its neuroprotective properties and broad-spectrum anti-inflammatory effects make IL-10 a promising candidate for treating neuropathic pain." @default.
• W2354474489 created "2016-06-24" @default.
• W2354474489 creator A5068923768 @default.
• W2354474489 date "2016-01-01" @default.
• W2354474489 modified "2023-09-25" @default.
• W2354474489 title "Sex Differences in the Efficacy of Combined IL-10 and IL-10R1 Gene Therapy for Neuropathic Pain in Mice" @default.
• W2354474489 cites W1498052765 @default.
• W2354474489 cites W1660050261 @default.
• W2354474489 cites W1876803907 @default.
• W2354474489 cites W1963558935 @default.
• W2354474489 cites W1966645567 @default.
• W2354474489 cites W1966698297 @default.
• W2354474489 cites W1975096151 @default.
• W2354474489 cites W1977051447 @default.
• W2354474489 cites W1981233223 @default.
• W2354474489 cites W1988768211 @default.
• W2354474489 cites W1989153207 @default.
• W2354474489 cites W1991900761 @default.
• W2354474489 cites W1992206444 @default.
• W2354474489 cites W1996426015 @default.
• W2354474489 cites W2006193913 @default.
• W2354474489 cites W2010545917 @default.
• W2354474489 cites W2012860078 @default.
• W2354474489 cites W2016474170 @default.
• W2354474489 cites W2025002129 @default.
• W2354474489 cites W2026821172 @default.
• W2354474489 cites W2031168791 @default.
• W2354474489 cites W2035605437 @default.
• W2354474489 cites W2040299229 @default.
• W2354474489 cites W2040831152 @default.
• W2354474489 cites W2046212133 @default.
• W2354474489 cites W2058020736 @default.
• W2354474489 cites W2064462697 @default.
• W2354474489 cites W2069814345 @default.
• W2354474489 cites W2081596796 @default.
• W2354474489 cites W2085642509 @default.
• W2354474489 cites W2088600148 @default.
• W2354474489 cites W2091186496 @default.
• W2354474489 cites W2095582751 @default.
• W2354474489 cites W2107277218 @default.
• W2354474489 cites W2126264913 @default.
• W2354474489 cites W2126575561 @default.
• W2354474489 cites W2131962374 @default.
• W2354474489 cites W2136961324 @default.
• W2354474489 cites W2142850882 @default.
• W2354474489 cites W2161074777 @default.
• W2354474489 cites W2170887912 @default.
• W2354474489 cites W2195259275 @default.
• W2354474489 cites W2196308323 @default.
• W2354474489 cites W2338132401 @default.
• W2354474489 cites W2884377952 @default.
• W2354474489 hasPublicationYear "2016" @default.
• W2354474489 type Work @default.
• W2354474489 sameAs 2354474489 @default.
• W2354474489 citedByCount "0" @default.
• W2354474489 crossrefType "journal-article" @default.
• W2354474489 hasAuthorship W2354474489A5068923768 @default.
• W2354474489 hasConcept C104317684 @default.
• W2354474489 hasConcept C111599444 @default.
• W2354474489 hasConcept C15744967 @default.
• W2354474489 hasConcept C203014093 @default.
• W2354474489 hasConcept C2777107010 @default.
• W2354474489 hasConcept C54355233 @default.
• W2354474489 hasConcept C71924100 @default.
• W2354474489 hasConcept C86803240 @default.
• W2354474489 hasConcept C98274493 @default.
• W2354474489 hasConceptScore W2354474489C104317684 @default.
• W2354474489 hasConceptScore W2354474489C111599444 @default.
• W2354474489 hasConceptScore W2354474489C15744967 @default.
• W2354474489 hasConceptScore W2354474489C203014093 @default.
• W2354474489 hasConceptScore W2354474489C2777107010 @default.
• W2354474489 hasConceptScore W2354474489C54355233 @default.
• W2354474489 hasConceptScore W2354474489C71924100 @default.
• W2354474489 hasConceptScore W2354474489C86803240 @default.
• W2354474489 hasConceptScore W2354474489C98274493 @default.
• W2354474489 hasLocation W23544744891 @default.
• W2354474489 hasOpenAccess W2354474489 @default.
• W2354474489 hasPrimaryLocation W23544744891 @default.
• W2354474489 hasRelatedWork W1600467070 @default.
• W2354474489 hasRelatedWork W163865703 @default.
• W2354474489 hasRelatedWork W1808111641 @default.
• W2354474489 hasRelatedWork W1986018857 @default.
• W2354474489 hasRelatedWork W2016560481 @default.
• W2354474489 hasRelatedWork W2154751358 @default.
• W2354474489 hasRelatedWork W2470893588 @default.
• W2354474489 hasRelatedWork W2943924499 @default.
• W2354474489 hasRelatedWork W3029846452 @default.
• W2354474489 hasRelatedWork W3029936022 @default.
• W2354474489 hasRelatedWork W3031489224 @default.
• W2354474489 hasRelatedWork W3031722978 @default.
• W2354474489 hasRelatedWork W3032551991 @default.
• W2354474489 hasRelatedWork W3115256823 @default.
• W2354474489 hasRelatedWork W3156563087 @default.
• W2354474489 hasRelatedWork W3199965232 @default.
• W2354474489 hasRelatedWork W3202151900 @default.
• W2354474489 hasRelatedWork W3209404169 @default.
• W2354474489 hasRelatedWork W2181390431 @default.
• W2354474489 hasRelatedWork W3041944365 @default.
• W2354474489 isParatext "false" @default.
• W2354474489 isRetracted "false" @default.

• next